Showing 361 - 380 results of 27,833 for search '(( 50 ((((we decrease) OR (nn decrease))) OR (a decrease)) ) OR ( end point decrease ))', query time: 0.83s Refine Results
  1. 361

    Differences among the classes of CAMs. by Daniel P. Bradley (10306893)

    Published 2025
    “…Some <i>N</i>-hydroxypyridinedione (HPD) HBV RNaseH inhibitors significantly reduced accumulation of capsids in HBV-replicating cells. A representative HPD <b>1466</b>, with a 50% effective concentration against HBV replication of 0.25 µM, decreased capsid and core protein accumulation by 50–90% in HepDES19 and HepG2.2.15 cells. …”
  2. 362
  3. 363
  4. 364
  5. 365
  6. 366
  7. 367

    DataSheet_2_A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells.docx by Yu-Ying Shi (15975992)

    Published 2023
    “…Introduction<p>Our previous research has found that degradation of palmitoyltransferase in tumor cells using a linear peptide PROTAC leads to a significant decrease in PD-L1 expression in tumors. …”
  8. 368

    DataSheet_1_A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells.docx by Yu-Ying Shi (15975992)

    Published 2023
    “…Introduction<p>Our previous research has found that degradation of palmitoyltransferase in tumor cells using a linear peptide PROTAC leads to a significant decrease in PD-L1 expression in tumors. …”
  9. 369
  10. 370
  11. 371
  12. 372
  13. 373
  14. 374
  15. 375
  16. 376
  17. 377
  18. 378
  19. 379

    PowerPoint Slides for: Urinary Periostin Excretion Predicts Renal Outcome in IgA Nephropathy by Hwang J.H. (3300987)

    Published 2016
    “…Histologically, group 3 patients were correlated with severe interstitial fibrosis/tubular atrophy (p = 0.004), interstitial inflammation (p = 0.007), hyaline arteriolosclerosis (p = 0.001) and glomerular sclerosis (p < 0.001). A higher initial uPOSTN/Cr level was associated with a greater decline in eGFR during follow-up (p = 0.043 when initial eGFR ≥60; p = 0.025 when eGFR <60 ml/min/1.73 m2), and the renal outcomes with end-stage renal disease (ESRD; p = 0.003), ESRD and/or eGFR decrease of >30% (p = 0.033) and ESRD and/or eGFR decrease of >50% (p = 0.046) occurred significantly more in group 3. …”
  20. 380